Jupiter Topco LLC Invests $844,000 in Disc Medicine, Inc. $IRON

Jupiter Topco LLC acquired a new position in Disc Medicine, Inc. (NASDAQ:IRON) in the 2nd quarter, HoldingsChannel reports. The fund acquired 11,555 shares of the company’s stock, valued at approximately $844,000.

Several other large investors have also modified their holdings of the business. Police & Firemen s Retirement System of New Jersey boosted its holdings in Disc Medicine by 3.3% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock valued at $533,000 after acquiring an additional 215 shares during the period. AlphaCentric Advisors LLC increased its stake in Disc Medicine by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock worth $254,000 after purchasing an additional 216 shares during the period. Kennedy Capital Management LLC increased its stake in Disc Medicine by 3.3% in the fourth quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock worth $740,000 after purchasing an additional 296 shares during the period. State of Wyoming bought a new stake in shares of Disc Medicine during the second quarter worth $25,000. Finally, Alliancebernstein L.P. boosted its stake in shares of Disc Medicine by 1.7% during the third quarter. Alliancebernstein L.P. now owns 24,540 shares of the company’s stock valued at $1,622,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Wall Street Zen cut shares of Disc Medicine from a “hold” rating to a “sell” rating in a research report on Saturday, August 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Wedbush boosted their price target on Disc Medicine from $88.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, September 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Disc Medicine in a research note on Tuesday, September 1st. Finally, HC Wainwright lifted their target price on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.70.

Insider Buying and Selling

In other Disc Medicine news, COO Jonathan Yu sold 8,796 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total value of $731,123.52. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO John D. Quisel sold 33,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the transaction, the chief executive officer owned 226,064 shares in the company, valued at $17,892,965.60. This represents a 12.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 208,108 shares of company stock valued at $15,799,739 over the last quarter. 3.76% of the stock is currently owned by company insiders.

Disc Medicine Price Performance

NASDAQ IRON opened at $79.23 on Monday. The firm’s fifty day simple moving average is $77.76 and its two-hundred day simple moving average is $70.48. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The firm has a market capitalization of $303.45 million, a P/E ratio of -12.04 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. Analysts forecast that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.